La Jolla regains Nasdaq listing compliance

By Angela McDaniels

Seattle, Jan. 12 - La Jolla Pharmaceutical Co. said it has regained compliance with Nasdaq's requirement that its stock close at $1.00 or higher for 10 consecutive days.

The company was first notified of its non-compliance in October. After being given an extension, La Jolla completed a one-for-five reverse stock split in December.

The company's stock closed at $3.95 on Thursday.

La Jolla is a biotechnology company based in San Diego that develops therapeutics to treat autoimmune diseases and inflammation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.